Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review

INTRODUCTION: Off-label rituximab is commonly used for patients with systemic lupus erythematosus (SLE) with extrarenal disease activity. METHODS: The outcomes and tolerability of rituximab in adult patients with non-renal SLE treated at our hospital from 2013 to 2020 were described. Patients were f...

Descripción completa

Detalles Bibliográficos
Autores principales: Sans-Pola, Carla, Danés, Immaculada, Bosch, Josep Àngel, Marrero-Álvarez, Patricia, Cortés, Josefina, Agustí, Antònia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248418/
https://www.ncbi.nlm.nih.gov/pubmed/37305139
http://dx.doi.org/10.3389/fmed.2023.1159794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248418/
https://www.ncbi.nlm.nih.gov/pubmed/37305139
http://dx.doi.org/10.3389/fmed.2023.1159794

Ejemplares similares